📰 Full Fact Sheet News
Full Fact Sheet News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Full Fact Sheet. Real-time updates on events, politics, business and more.
April 20, 2022
21.04.2022 - Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary ...
March 21, 2022
EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies - read this article along with other careers information, tips and advice on BioSpace
December 25, 2021
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities - read this article along with other careers information, tips and advice on BioSpace
December 23, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation.
December 16, 2021
16.12.2021 - AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical ...
December 9, 2021
09.12.2021 - AstraZenecas EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses ...